Business
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will
About this update from Vor Biopharma Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit. JMP Securities Hematology and Oncology SummitFireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET Location: Virtual About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com. Contact: Media & InvestorsSarah Spencer +1 [email protected] \nSource: Vor Biopharma","length":2169,"tagName":"div"}]